AR022283A1 - Aminas substituidas de espirofuropiridinas novedosas utiles en terapia - Google Patents

Aminas substituidas de espirofuropiridinas novedosas utiles en terapia

Info

Publication number
AR022283A1
AR022283A1 ARP000100156A ARP000100156A AR022283A1 AR 022283 A1 AR022283 A1 AR 022283A1 AR P000100156 A ARP000100156 A AR P000100156A AR P000100156 A ARP000100156 A AR P000100156A AR 022283 A1 AR022283 A1 AR 022283A1
Authority
AR
Argentina
Prior art keywords
alkyl
zero
halogen
optionally substituted
hydrogen
Prior art date
Application number
ARP000100156A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR022283A1 publication Critical patent/AR022283A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Un compuesto de la formula (1) en la cual NRR1, está unido en la posicion 5 o 6 del anillo de furopiridina; R es hidrogeno, alquilo C1-4, COR2; R1 es(CH2)nAr, CH2CH=CHAr o CH2C:::CAr; n es 0 a 3; A es N o NO; Ar es un anillo aromático oheteroaromáti co de 5 o 6 miembros que contiene de cero a cuatro átomosde nitrogeno, de cero a un átomo de oxígeno y de cero a un átomo de azufre; o un sistema de anillos aromático o heteroaromático fusionados de 8, 9 o 10miembros que contiene decero a cuatro áto mos de nitrogeno, de cero a un átomo de oxígeno y de cero a un átomo de azufre; cualquiera de los cuales pueden estaropcionalmente substituidos con uno o dos substituyentes independientemente seleccionados del grupo formado porhalogeno, trifluoromet ilo o alquilo C1-4; R2 eshidrogeno, alquilo C1-4, alcoxilo C1-4 o un anillo de fenilo opcionalmente substituido con uno a tres de los siguientes substituyentes: halogeno, alquilo C1-4,alquenilo C2-4, alquinilo C2-4, OH,alquilo OC1-4, CO2R2, -CN, -NO 2, -NR3R4 o -CF3; R3, R4 y R5 son independientemente hidrogeno, alquilo C1-4 o un anillo defenilo opcionalmente substituido con uno a tres de los siguientes substituyentes: halogeno, alquilo C1-4, alquenilo C2-4,alquinilo C2-4, OH, alquilo OC1-C4,CO 2R2, -CN, -NO2 o -CF3, y enantiomeros de los mismos, y sales farmacéuticamente aceptables de los mismos, procesos para prepararlos, composiciones que loscontienen y su uso en terapia, especialmente en eltratamiento o profilaxis de trastornos psicoti cos y trastornos de deterioro intelectual.
ARP000100156A 1999-01-15 2000-01-13 Aminas substituidas de espirofuropiridinas novedosas utiles en terapia AR022283A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900100A SE9900100D0 (sv) 1999-01-15 1999-01-15 New compounds

Publications (1)

Publication Number Publication Date
AR022283A1 true AR022283A1 (es) 2002-09-04

Family

ID=20414101

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100156A AR022283A1 (es) 1999-01-15 2000-01-13 Aminas substituidas de espirofuropiridinas novedosas utiles en terapia

Country Status (34)

Country Link
US (2) US6995167B2 (es)
EP (1) EP1147114B1 (es)
JP (1) JP2002534525A (es)
KR (1) KR100660496B1 (es)
CN (1) CN1132837C (es)
AR (1) AR022283A1 (es)
AT (1) ATE240960T1 (es)
AU (1) AU775433B2 (es)
BR (1) BR9916906A (es)
CA (1) CA2359990A1 (es)
CZ (1) CZ20012554A3 (es)
DE (1) DE69908185T2 (es)
DK (1) DK1147114T3 (es)
EE (1) EE04528B1 (es)
ES (1) ES2200590T3 (es)
HK (1) HK1040517B (es)
HU (1) HUP0200513A3 (es)
ID (1) ID30034A (es)
IL (1) IL144266A0 (es)
IS (1) IS6000A (es)
MY (1) MY118109A (es)
NO (1) NO20013478L (es)
NZ (1) NZ512733A (es)
PT (1) PT1147114E (es)
RU (1) RU2233282C2 (es)
SA (1) SA00200987B1 (es)
SE (1) SE9900100D0 (es)
SI (1) SI1147114T1 (es)
SK (1) SK9932001A3 (es)
TR (1) TR200102042T2 (es)
TW (2) TWI227237B (es)
UA (1) UA71598C2 (es)
WO (1) WO2000042044A1 (es)
ZA (1) ZA200105527B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
IL158735A0 (en) * 2001-06-01 2004-05-12 Astrazeneca Ab Novel ligand for nicotinic acetylcholine receptors useful in therapy
BR0213612A (pt) 2001-10-02 2004-08-24 Upjohn Co Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
MXPA04010190A (es) * 2002-04-18 2005-02-03 Astrazeneca Ab Compuestos heterociclicos.
BR0309342A (pt) * 2002-04-18 2005-02-15 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0309343A (pt) * 2002-04-18 2005-02-15 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
CA2495248A1 (en) 2002-08-30 2004-03-11 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CA2499128C (en) 2002-09-25 2012-07-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
ATE378048T1 (de) * 2002-12-06 2007-11-15 The Feinstein Inst Medical Res Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
WO2004063201A1 (ja) * 2003-01-08 2004-07-29 Mitsubishi Pharma Corporation 統合失調症治療剤
WO2005000250A2 (en) * 2003-06-24 2005-01-06 Johns Hopkins University Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor
KR20060094962A (ko) 2003-10-21 2006-08-30 아스트라제네카 아베 스피로푸로피리딘 아릴 유도체
US7045530B2 (en) 2003-12-22 2006-05-16 Abbott Laboratories Spirocyclic quinuclidinic ether derivatives
RU2417225C2 (ru) 2004-03-25 2011-04-27 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
RU2448111C2 (ru) * 2006-08-21 2012-04-20 Дженентек, Инк. Соединения азабензофуранила и способ их применения
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
MY157518A (en) 2008-06-20 2016-06-15 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
DK2350090T3 (en) 2008-10-17 2015-09-07 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
KR20180011888A (ko) 2008-11-19 2018-02-02 포럼 파마슈티칼즈 인크. (ｒ)-７-클로로-ｎ-(퀴누클리딘-３-일)벤조［ｂ］티오펜-２-카르복사미드 및 그 약학적으로 허용가능한 염을 이용한 인지 장애의 치료
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
BRPI1014793A2 (pt) * 2009-05-11 2016-04-05 Envivo Pharmaceuticals Inc tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047174A1 (en) 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
RS54742B1 (sr) 2010-05-17 2016-10-31 Forum Pharmaceuticals Inc Kristalni oblik (r)-7-hlor-n-(hinuklidin-3-il)benzo[b]tiofen-2-karboksamid hidrohlorid monohidrata
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
ES2714314T3 (es) 2012-04-12 2019-05-28 Xenon Pharmaceuticals Inc Síntesis asimétrica para compuestos de espiro-oxindol útiles como agentes terapéuticos
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
WO2014202999A1 (en) 2013-06-21 2014-12-24 Takeda Cambridge Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2074441T3 (es) * 1987-10-05 1995-09-16 Yamanouchi Pharma Co Ltd Compuestos espiro heterociclicos y su preparacion.
JPH0195922A (ja) 1987-10-08 1989-04-14 Mazda Motor Corp 車両のサスペンション制御装置
PL183933B1 (pl) * 1994-08-24 2002-08-30 Astra Ab Związki spiroazabicyklo, sposób wytwarzania związku spiroazabicyklo i kompozycja farmaceutyczna
DK0842178T3 (da) * 1995-07-28 2001-08-06 Abbott Lab Furopyridin, thienopyridin, pyrrolopyridin og beslægtede pyrimidin-, pyridazin- og triazinforbindelser, som er nyttige til regulering af kemisk synaptisk transmission
US6156783A (en) 1996-04-30 2000-12-05 Smithkline Beecham P.L.C. Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
KR20010086167A (ko) 2001-09-08
CN1337964A (zh) 2002-02-27
WO2000042044A1 (en) 2000-07-20
EP1147114A1 (en) 2001-10-24
ES2200590T3 (es) 2004-03-01
US20050250802A1 (en) 2005-11-10
AU775433B2 (en) 2004-07-29
TR200102042T2 (tr) 2002-05-21
US6995167B2 (en) 2006-02-07
SI1147114T1 (en) 2003-12-31
BR9916906A (pt) 2001-10-30
CA2359990A1 (en) 2000-07-20
US7196096B2 (en) 2007-03-27
DE69908185D1 (de) 2003-06-26
MY118109A (en) 2004-08-30
NO20013478D0 (no) 2001-07-13
EE200100370A (et) 2002-10-15
UA71598C2 (en) 2004-12-15
CZ20012554A3 (cs) 2002-01-16
DE69908185T2 (de) 2004-06-03
EE04528B1 (et) 2005-08-15
ZA200105527B (en) 2002-10-04
JP2002534525A (ja) 2002-10-15
HUP0200513A2 (en) 2002-06-29
SK9932001A3 (en) 2002-04-04
EP1147114B1 (en) 2003-05-21
TW200413387A (en) 2004-08-01
US20030149065A1 (en) 2003-08-07
NO20013478L (no) 2001-09-14
RU2233282C2 (ru) 2004-07-27
HK1040517A1 (en) 2002-06-14
ATE240960T1 (de) 2003-06-15
IL144266A0 (en) 2002-05-23
HUP0200513A3 (en) 2004-07-28
NZ512733A (en) 2003-08-29
KR100660496B1 (ko) 2006-12-22
HK1040517B (zh) 2003-09-05
AU2334300A (en) 2000-08-01
ID30034A (id) 2001-11-01
DK1147114T3 (da) 2003-09-15
SE9900100D0 (sv) 1999-01-15
CN1132837C (zh) 2003-12-31
PT1147114E (pt) 2003-10-31
IS6000A (is) 2001-07-12
SA00200987B1 (ar) 2006-11-07
TWI227237B (en) 2005-02-01

Similar Documents

Publication Publication Date Title
AR022283A1 (es) Aminas substituidas de espirofuropiridinas novedosas utiles en terapia
AR035557A1 (es) Un metodo para el tratamiento de desordenes proliferativos de las celulas asociadas con una actividad alterada de la cinasa dependiente de las celulas, un derivado de 3-ureido-pirazol, un procedimiento para su preparacion y una composicion farmaceutica que comprende dicho derivado
MY116761A (en) Novel spiroazabicyclic heterocyclic compounds.
HRP20080477T3 (en) Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
RS50300B (sr) Derivati arilmetil-karbonil-amino-tiazola za upotrebu kao antitumorna sredstva
HUP0002461A2 (hu) Triciklusos benzotiepin- vagy benzoxepinszármazékok és ezeket tartalmazó gyógyszerkészítmények
TR200401007T4 (tr) Azabisiklik karbamatlar ve bunların, alfa-7 nikotinik asetilkolin reseptör agonistleri olarak kullanımları
MY123580A (en) Novel biarylcarboxamides
HUP0104816A2 (hu) 3-Azabiciklo[3.1.0]hexán-származékok mint ópiát receptor ligandumok és eljárás előállításukra
CO5070570A1 (es) DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE
NZ336302A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
FI915970A0 (fi) Laekemedel, som aer nyttiga vid vaord av cancer och som har antihistaminegenskaper.
SE9702799D0 (sv) New compounds
BR9307580A (pt) Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano
MXPA05007494A (es) Nuevos compuestos.
BG103258A (en) Azinyloxy- and phenoxydiaryl derivatives of carboxylic acids, their preparation and application as mixed eta/etb endothelin-receptor antagonists
ATE231488T1 (de) Harnstoffderivate und ihre anwendung als integrin-inhibitoren
SE8307133D0 (sv) Carboxamido-derivatives of 5h-1,3,4-thiadiazolo(3,2-a)pyrimidines and process for their preparation
BR9812239A (pt) Composto, formulação farmacêutica, uso do composto, processos para o tratamento de distúrbios, para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e, para a preparação do composto
HUP0401883A2 (hu) Muszkarin agonisták és ezeket tartalmazó gyógyászati készítmények
HRP20070030T3 (en) Derivatives of benzothiazine and benzothiadiazine, procedure for their preparation and pharmaceutical compositions containing them
AR023111A1 (es) Derivados de sulfonamida utiles como antagonistas del receptor 5-ht7, un procedimiento para su preparacion y composicion farmaceutica que los comprenden
DE68913365D1 (de) 4-Amino-3-carboxynaphthyridin-Derivate, ihre Herstellung und pharmazeutische Zusammensetzungen.
CO5251379A1 (es) Nuevos derivados aminosubstituidos ramificados de 3- amino-1-fenil-1h[1,2,4] triazol, procedimientos para su preparacion y composiciones farmaceuticas que los contienen
HUP0303457A2 (hu) Antimikrobiális hatású 2-piridonok, ezeket tartalmazó készítmények és alkalmazásuk

Legal Events

Date Code Title Description
FA Abandonment or withdrawal